Krystal Biotech, Inc.

NASDAQ:KRYS

125.36 (USD) • At close June 2, 2025
Bedrijfsnaam Krystal Biotech, Inc.
Symbool KRYS
Munteenheid USD
Prijs 125.36
Beurswaarde 3,622,741,032
Dividendpercentage 0%
52-weken bereik 122.8 - 219.34
Industrie Biotechnology
Sector Healthcare
CEO Mr. Krish S. Krishnan M.B.A., M.S.
Website https://www.krystalbio.com

An error occurred while fetching data.

Over Krystal Biotech, Inc.

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved

Vergelijkbare Aandelen

ImmunityBio, Inc. logo

ImmunityBio, Inc.

IBRX

2.67 USD

Travere Therapeutics, Inc. logo

Travere Therapeutics, Inc.

TVTX

15.52 USD

Establishment Labs Holdings Inc. logo

Establishment Labs Holdings Inc.

ESTA

33.97 USD

Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc.

XENE

30.07 USD

Addus HomeCare Corporation logo

Addus HomeCare Corporation

ADUS

111.2 USD

Ligand Pharmaceuticals Incorporated logo

Ligand Pharmaceuticals Incorporated

LGND

101.64 USD

Dynavax Technologies Corporation logo

Dynavax Technologies Corporation

DVAX

9.84 USD

ModivCare Inc. logo

ModivCare Inc.

MODV

2.2 USD

Supernus Pharmaceuticals, Inc. logo

Supernus Pharmaceuticals, Inc.

SUPN

31.91 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)